Cell Source, Inc. (CLCS) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US15114L1044
Cell Source, Inc. financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 0.00 USD | – |
| Operating income | -3.85 m USD | -2.73 m USD |
| EBIT | -4.51 m USD | – |
| Net income | -4.77 m USD | -4.64 m USD |
| Diluted EPS – continuing operations | -0.14 USD | – |
Full history since 2012, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Cell Source, Inc.
Cell Source, Inc., a biotechnology company, engages in developing cell therapy treatments based on the management of immune tolerance. Its lead product is the Veto Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking of immune responses. The company's Veto Cell technology is used in various applications, including treatment of lymphoma, leukemia, and multiple myeloma through facilitation of the stem cell transplantation acceptance, as well as treatment of end stage kidney disease; other non-malignant organ diseases through organ transplantation; and various cancers and non-malignant diseases. Cell Source, Inc. was founded in 2012 and is headquartered in New York, New York.
More stocks
- Black Hawk Acquisition Corp (BKHA)
- PARKS AMERICA, INC (PRKA)
- Creatd, Inc. (CRTD)
- FORUM MARKETS Inc (FRMM)
- Western Alaska Minerals Corp (WAM.V)
- InspireMD, Inc. (NSPR)
- JONES SODA CO. (JSDA)
- SEAFARER EXPLORATION CORP (SFRX)
- RAVE RESTAURANT GROUP, INC. (RAVE)
- Paradium AI, Inc. (PAAI)
- HARTE HANKS INC (HHS)
- BriaCell Therapeutics Corp. (BCTX)
Not investment advice. All data without warranty, price as of 28.10.2026. Details in the risk notice.